CD274 and neoplasm: The KEYNOTE-062 trial revealed that pembrolizumab significantly benefits patients with PD-L1 combined positive score (CPS) ≥10 or MSI-H/dMMR tumor mutations [5], but fails to demonstrate survival advantages in patients with lower CPS scores [6].